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1. INTRODUCTION 
 
Over the last few years there has been a considerable increase in the number of patients taking drugs 
that, in different ways, are able to reduce the risk of thrombotic events. 
Individuals at risk of thrombosis include patients with prosthetic valves, those with atrial fibrillation or 
deep vein thrombosis. The drugs prescribed to these patients for long-term treatments can be grouped 
into two broad categories: anti-platelet agents and oral anticoagulants. Both these categories of drugs 
reach their objective by modifying the physiological coagulation process. 
The intake of anti-platelet agents per se is  not  contra-indicated  with a view to performing oral 
surgery, since the onset of severe hemorrhage is an event considered as extremely rare in the literature. 
Treatment with oral anticoagulants, instead, requires careful monitoring of INR, and it is likely that 
local haemostatic agents will be required. 
In this paper we will consider the pharmacologically induced coagulation deficits in patients taking oral 
anticoagulants, anti-platelets or fibrinolytics; we will examine the clinical protocols suggested in the 
Literature  to follow in order to perform safely even the simplest dental treatment. 
The purpose of this paper, after a brief evaluation of operational protocols in the literature, is to 
highlight the effectiveness of a new drug formulation made in collaboration with the Faculty of 
Pharmacy, University "Federico II" for hemostasis control in post extraction care in patients taking 
anticoagulants. 
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2. HEMOSTASIS 
Several routine dental procedures may cause the bleeding of the oral mucosa which, in most cases, can 
be controlled without difficulty and with minimal blood loss from the patient. In some individuals, 
however, the physiological processes that allow the organism to control bleeding (hemostasis) are 
altered, which may favor the onset of bleeding. Although there are numerous diseases that can affect 
these mechanisms, the most frequent cause of hemostasis alterations is taking medications for the 
prevention of thrombosis, that is of drugs that act on the platelet phase (anti-platelet) and clotting 
(anticoagulants) of the hemostatic process. 
Hemostasis is a physiological defense process and in vivo opposes any bleeding caused by injury or 
rupture of a blood vessel. It is this physiological process that ensures the integrity of the blood stream. 
This process is based on the balance between two phenomena: the formation of the clot, which has the 
function of protecting from bleeding, and the dissolution of the clot, which protects against thrombotic 
events. This is  a so-called ‘two-way process’. 
Hemostasis consists of four basic stages: also called ‘vascular’ phase (primary hemostasis), ‘platelet’ 
phase, ‘coagulation’ phase (secondary hemostasis) and ‘fibrinolysis’. 
2.1 PRIMARY HEMOSTASIS 
During the vascular phase the damaged vessels attempt to minimize blood loss; they do so through a 
vascular vasoconstriction which, however, is not able to ensure permanent hemostasis unless dealing 
with  capillary lesions. Even in case of more severe injuries, the vasoconstrictor phenomenon is of 
considerable importance;  such stimulus is present also during the successive stages of the coagulation 
process. The secretion of the following substances will take place: thromboxane, EDRF, NO and 
prostacyclin. In the same phase, the platelets release serotonin and noradrenalin that have a 
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vasoconstrictor effect. 
The platelet phase has a role of considerable importance within the process of blood clotting. Very 
broadly speaking, we can distinguish five main stages: ‘adhesion of the first platelets to the damaged 
area’, the platelets interact (Glic.Ib) with the collagen of the perivascular tissue facilitated by the 
presence of von Willebrand factor; ‘activation of platelets adherent to the damaged surface’; ‘release of 
chemical signals contained in activated platelets’; ‘activation cascade of other platelets’ stimulated by 
the previous step and finally ‘platelet aggregation’; the latter is a reversible process because platelets 
have a tendency to disperse and, if the phase of coagulation does not take place, there is a resumption 
of the bleeding. The platelet phase, therefore, while being very important in the haemostatic process, is 
not sufficient to obtain definitive haemostasis. 
2.2  SECONDARY HEMOSTASIS 
 The coagulation phase (or plasmatic) is the most important step in the process of blood coagulation. 
Under normal conditions, it leads to the arrest of the permanent blood loss. The plasma phase is 
finalized to the transformation of fibrinogen (a glycoprotein present in the bloodstream) into a fibrin 
clot, a protein that, in cooperation with the platelets, occludes the damaged area. In the last fibrinolytic 
stage there is the presence of another protein, plasminogen, which when converted to plasmin, degrades 
the fibrin clot finally restoring the vessel integrity (restitutio ad integrum); fibrinolysis, therefore, 
although part of the haemostatic process, is still an anti-haemostatic component 
(63)
. 
The coagulation cascade is accomplished via two mechanisms that converge on a common pathway 
(Fig. 1) 
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Figure 1: The coagulative cascade 
EXTRINSIC MECHANISM: cell membranes contain the tissue thromboplastin, and further to a lesion, 
this factor appears in the plasma, where it causes activation of the proconvertin (factor VII). This factor 
acts directly on the Stuart factor (factor X), activating it. Also thrombin  appears to have an enhancer 
effect on the extrinsic mechanism, accelerating the activation of proconvertin. 
INTRINSIC MECHANISM: its triggering depends on the plasma contact with negatively charged 
substances such as collagen and proteins of the basement membrane of the endothelium. This 
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determines the activation of the Hageman factor (factor XII) in a process which also involves two other 
factors:  kininogen and prekallikrein. Factor XII activates factor XI (plasma thromboplastin factor), 
which in turn activates the Christmas factor (factor IX). Factor IXa, together with platelets, Ca ++ and 
phospholipids, cooperates with the anti-hemophilic globulin (factor VIII) for the activation of the Stuart 
factor. 
COMMON PATHWAY: both previous processes converge in the common pathway, beginning with 
the activation of factor X; factor Xa 9 begins the conversion of prothrombin into thrombin, and this 
causes a positive feedback activation: thrombin activates proaccelerin (factor V), which binds to factor 
Xa to form the so-called "prothrombin activator"; while thrombin negatively regulates its activation by 
activating two plasma proteins (C and D) that inhibit proaccelerin and  antihemophilic globulin. 
Thrombin cuts the fibrinogen into insoluble fibrin; the stabilization of the fibrin (ie promoting the 
formation of covalent bonds between fibrin monomers) is made possible by a stabilizing factor (Factor 
XIII), previously activated by thrombin. Coagulation occurs rapidly, since each enzyme molecule 
activates several enzyme molecules of the next stage, amplifying the whole process. The final product 
is the coagulation cap (red clot), in which the fibrin constitutes the fibrous network of a gelatinous mass 
in which we find all the blood cells and a liquid part formed by the plasma
(62)
. 
CLOT RETRACTION: Once formed, the clot decreases its mass; there is, in fact, the draining of serum 
(ie the plasma deprived of the fibrinogen). The retraction is used to promote the adhesion of the clot to 
the injured tissues. 
FIBRINOLYSIS: the dissolution of the clot occurs thanks to the demolition of fibrin by plasmin, 
derived from inactive plasminogen. In addition, plasmin is capable of degrading important X factors of 
coagulation 10: fibrinogen, factors VIII, V, XII. Multiple factors are capable of converting 
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plasminogen into plasmin. The main one is the tissue plasminogen activating factor, released from 
damaged tissues. Even some factors of the intrinsic coagulation mechanism are capable of converting 
plasminogen into plasmin. This is a clear confirmation of the fact that the coagulation and fibrinolytic 
process are in dynamic equilibrium. 
2.3 WOUND HEALING 
The healing  following a wound begins with the formation of a clot consisting of fibrin and platelets. 
This clot has the immediate effect of blocking the blood loss, and so as a result, the fibrin and the 
growth factors contained in the platelets allow the repair of new tissue. 
Fibrin is rapidly invaded by leukocytes which are the first cells to start the neo-vasculature; the white 
blood cells contain VEGF, the most potent among the vascular endothelial growth factors. The platelet 
growth factors (PDGF) are equally involved in neo-vasculature and fibrin serves as the tissue matrix to 
allow the reconstruction. Healing can occur by primary or secondary intention. 
Healing by primary intention (surgical wound): the loss of substance caused by surgical incision is 
filled by a blood clot consisting of a network of fibrin which contains red blood cells, white blood cells, 
platelets and other blood components. In this phase, the clot, very adherent to the walls, can also be 
easily removed by small traumas. In the following period the macrophages appear. They are 
mononuclear cells with phagocytic capacity, and therefore active in cleaning up the wound from fibrin 
and cellular debris. 
After the first 24-48 hours a granulation tissue is formed consisting of some mobile elements that 
originates from the connective fibroblasts. They  penetrate into the wound along the filaments that 
make up the network of fibrin, replacing them with fibers with high capacity contractile myofibrils. 
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Simultaneously, on the margins of the wound begins the production of vascular and later lymphatic 
formations that extend gradually towards the center until they meet with the same vascular formations 
on the opposite side. Once the anastomosis of the stumps has taken place a channeling process starts by 
which cellular cords become vessels and form a new vascular network. Fibroblasts also have the ability 
to secrete a substance, hyaluronic acid, the active component in the formation of collagen fibers; in this 
phase the wound appears swollen and reddened for the richness of newly formed vascular tissue. 
With the passing of time the number and activity of fibroblasts decreases, blood capillaries are reduced 
and simultaneously the number of collagen fibers increases. The transformation of the granulation 
tissue into scar tissue takes place; its characteristics are low elasticity, reduced innervations and blood 
supply, modest epithelialization, the absence of skin appendages. 
This process leads to the formation of a solid scar in about two weeks. During this time it becomes 
gradually contracted because of the action of the myofibrils. 
Healing by secondary intention: this healing is characterized by a significant loss of tissue which leads 
to a more intense inflammatory reaction and the formation of larger amounts of granulation tissue 
which, starting from the bottom of the wound progresses, very slowly, upwards. It is a longer and more 
tedious process than primary healing, often responsible for serious imperfections. The grainy look, 
which gives it its name, becomes evident and its rich vasculature may easily lead to bleeding. 
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3. MANAGEMENT OF PATIENTS AFFECTED BY COAGULOPATHY 
 
The management of patients receiving anti-platelet agents and anticoagulants, as they suffer from 
conditions at high risk of thrombosis, is a big commitment. For these patients wound healing is a slow 
and difficult process for the interference of  anticoagulant drugs with the mechanisms of formation of 
the clot (responsible for immediate hemostasis). 
In addition, cardiovascular patients often take, in combination with anticoagulants and anti-platelet 
therapies, also medications that can cause oral conditions such as: dry mouth syndrome and lichenoid 
reactions (B- blockers and anti-hypertensives), hypertrophic hyperplastic gingivitis (Ca - antagonists 
such as nifedipine), recurrent oral ulcers (anti-hypertensives as alpha-methyldopa); which is why the 
patient should be assessed as a whole. 
These patients may be suffering from the following diseases: chronic stable angina, polycythemia vera, 
unstable angina, acute myocardial infarction, transient ischemic attack, ischemic stroke, severe carotid 
artery stenosis, atrial fibrillation (Table I). 
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Table I. Anti-Coagulant Therapeutic Indications  
Heart Diseases  
- Atrial Fibrillation 
- Prosthetic valve 
- post- infarction 
Trauma surgery pathologies and vascular diseases  
- Peripheral arterial Disease 
- Deep Vein Thrombosis 
- Pulmonary Embolism 
Reconstructive Vascular Surgery 
Congenital or acquired pathologies  
-Reduced sensitivity to activated protein C 
- Deficiency of physiological blood clotting factors  
- Fibrinolysis alteration  
- thrombocytosis 
- Blood hyperviscosity 
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The behavior of the dentist has to adjust to the different kind of treatment the patient is undergoing. If a 
patient is following an anti-platelet therapy, the monitoring of the therapy is not needed. Actally, in 
patients following an anti-platelet therapy, the monitoring of the bleeding time or of any other types of 
assessment is not necessary immediately before the intervention, since the anti-platelet therapy, unlike 
the anticoagulant one, is not subject to major variations over time and it is rare that in such cases a 
patient reaches high bleeding times. In fact, in patients following an anti-platelet therapy with low-dose 
aspirin, the risk of bleeding is very low and it occurs  only in very rare cases when the bleeding time 
exceeds 20 minutes. 
In the past, the risk of excessive bleeding led clinicians to discontinue anti-platelet therapy with low-
dose aspirin before performing surgery, even if doing so exposed the patient to the risk of a thrombotic 
event 
(44,45)
 . 
Today such behavior is no longer shared on the basis of numerous reviews in the literature, which 
suggest that the majority of surgical procedures in the oral cavity can be implemented successfully 
without suspending the anti-platelet therapy with low-dose aspirin. A study of 51 patients on chronic 
anti-platelet therapy who underwent surgery in the oral cavity without discontinuation of the therapy, 
has recorded a single case of excessive intra-operative bleeding and no cases of postoperative bleeding. 
The only bleeding episode occurred after the extraction of a third molar and hemostasis was in any case 
obtained through stitching and the application of gauze soaked in tranexamic acid 
(46)
. 
In conclusion, we can state that there is no need to suspend or change the chronic anti-platelet therapy 
before performing surgery to the oral cavity. In the rare cases of a patient requiring urgent surgery and  
bleeding time exceeding 20 minutes, desmopressin or any other similar medication can be administered 
in order to reduce bleeding time 
( 47)
. 
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3.1 HEMATOCHEMICAL  EVALUATION PARAMETERS  
The therapeutic use of oral anticoagulants, especially if prolonged over time, requires, instead, an 
extremely accurate monitoring. The measurement of the anticoagulant response, carried out  by regular 
laboratory controls, allows to ascertain the presence of an anticoagulant effect for the duration of the 
treatment and to maintain the coagulation levels within the recommended range for the pathology to be 
treated. 
The values of such a range were derived from longitudinal studies of numerous patients at risk of 
thrombosis, which allowed to obtain these minimum and maximum statistical values able to reduce 
thrombotic phenomena without causing spontaneous hemorrhage. 
The required dosage of the drug to reach the individual therapeutic range varies from subject to subject. 
This complicates the treatment protocol and for this reason the attempts to reach a stable therapeutic 
range are often as long as a few months. Once the goal of a stable range has been reached, the 
coagulation checks are carried out only every 15-20 days . 
The anticoagulation control is always performed by means of a test introduced by Quick in 1935, 
which explores the extrinsic pathway of the coagulation as it is sensitive to a reduction of some vitamin 
K dependent coagulation factors (II, VII and X) inhibited by oral anticoagulants. The test measures the 
time it takes for the blood to coagulate following the addition of an optimum amount of tissue 
thromboplastin and calcium ion. The tissue thromboplastin interacts with the various vitamin K 
dependent factors and determines the formation of thrombin from prothrombin. A prolonged clotting 
time indicates the inhibition of such coagulation factors.  
Following a number of drawbacks occurred over the years linked to the use of the PT, probably caused 
by the progressive deterioration of thromboplastin used as a reagent, numerous attempts have been 
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made in order to standardize the various techniques used in the evaluation of the activity of oral 
anticoagulants. 
In 1976 the "WHO has indicated as a primary reference thromboplastin a substance called 67:40 by the 
International Comittee on Thrombosis and Haemostasis (ICTA), ie a thromboplastin derived from 
human brain. The limited availability and the impossibility of sending the reagent in all parts of the 
world have pushed the ICTA to propose that the European Community Bureau of Reference undertake 
a calibration study of thromboplastin internationally. Comparing a thromboplastin to another is difficult 
for a whole series of biochemical and methodological reasons. These difficulties have been avoided in 
part, within the therapeutic range of anticoagulants, by introducing a linear relationship of the 
logarithms of prothrombin time, calculated by performing an orthogonal regression equation, and 
taking the gradient as the relation index. It was proposed that the gradient of the correlation between 
any thromboplastin  and the primary international reference preparation should be called "International 
Sensitivity Index" (ISI) in accordance with the WHO recommendations. The manufacturers were thus 
invited to introduce, as soon as possible, their own internal standard for the thromboplastin produced 
by them and to indicate by means of a label the gradient of the batch of the material with respect to the 
international reference thromboplastin. 
It was then introduced a new prothrombin index as an expression of the time defined INR (International 
Normalized Ratio). The INR is therefore the prothrombin ratio that would be observed if the 
prothrombin used were the international reference material, derived from a standard preparation and 
filed with the WHO. The INR is equal to the ratio of the patient's prothrombin time raised to the power 
of the ISI value (International Sensitivity Index) for the analytical system used. 
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The normal value is INR 1, while higher values indicate a prolonged prothrombin time, which means 
difficulty in coagulation. 
Currently the monitoring of the action of a given oral coagulant is based on the use of the INR 
(48)
. The 
adoption of the INR has made it possible to have a unitary system for recommended therapeutic ranges 
(range) in various diseases (Table II) and, in effect, thanks to it  polycentric clinical studies have been 
carried out including the comparison of data from different laboratories. 
After the establishment of the therapy and the achievement of  optimal coagulation levels, the time 
interval that elapses between the various controls of the INR can be gradually lengthened, consistently 
with the stability of the checks made, but the interval rarely exceeds 3 or 4 weeks, because of the many 
factors (diet, physical activity, fever, climate and drug interactions) that can interfere with 
anticoagulant activity. This monitoring is recorded, along with the administered doses, on a card that is 
updated at every check and delivered to the patient with the recommendation to produce it before 
undergoing any medical or surgical treatment. 
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Table II : INR suggested values in conditions requiring anti-coagulant therapy  
Clinical Situation INR INTERVAL Duration   
Mitral commisurotomy  
2.0-3.0  
  
3 months 0 sine die  
   
Cardiac Intracavitary thrombosis  
Non-rheumatic atrial fibrillation  
Heart Biological Prosthetic valves 
Mitral valve stenosis  
Acute myocardical Infarction  2.8 - 4.8  3 years  
Heart Mechanical Prosthetic valves 3.0 - 4.5  Sine die  
Deep Vein Thrombosis 
2.0 - 3.0  
3-6 Months 0 Sine 
die  Pulmonary Embolism 
Peripheral arterial Disease 
2.0 - 4.0  
Sine die  
   
Reconstructive Vascular Surgery 
DVT Prevention in Surgery  2.0 - 2.5  Days 4-10  
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3.2 SUGGESTED PROTOCOLS FOR CLINICAL TREATMENT 
 
Since the early 90s, patients on anticoagulants who had to undergo dental procedures associated with 
bleeding risk were made to discontinue the therapy or, in cases where this was not possible, the patient 
was hospitalized in order to ensure a better control of the coagulation before and after the operation 
(49)
. 
The discontinuation of the anticoagulant therapy entailed an increased risk of thrombosis and imposed 
a difficult collaboration between the various specialists who had treated the patient. For these reasons, 
in later years, and following the introduction of INR monitoring method by the WHO (1983) the 
general attitude became not to reduce nor discontinue the anticoagulation therapy, but to keep it 
unchanged 
(50)
; the works reported in the literature are directed, on the one hand, to investigate the 
difference in incidence of thrombotic complications and / or bleeding in the patients whose therapy has 
been suspended from those that continue the therapy; on the other, to assess whether haemostatic 
agents are able to control postoperative bleeding. A 1999 study, conducted on 150 patients (359 
extractions), reported bleeding complications in 11 patients with INR between 1.5 and 4.0. in all cases 
haemostasis was easily obtained with the aid of local haemostatic (gelatin sponge, fibrin glue, sutures) 
(51)
. Other studies have confirmed a low number of bleeding complications in patients undergoing 
anticoagulant therapy in oral surgery. Martinowitz et al. 
(52)
 in patients with INR range 2.5-4.0 observed 
no bleeding complications after 63 extractions. Even Bonder et al. 
(53)
 after 69 extractions have not 
detected bleeding with INR greater than 2 in 49 out of 69 patients. 
 
3.3 DENTAL DISORDERS IN PATIENTS UNDERGOING ANTI-
COAGULANT/ANTI-AGGREGANT TREATMENTS  
It must be emphasized that there are two issues to be considered more carefully when planning the 
treatment of a patient on anticoagulant therapy. They are: 
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• the type of dental treatment 
• the INR values and the underlying disease (INR range)(8-18) 
Type of dental treatment 
Not all dental treatments expose the patients to the risk of bleeding, as not all cause bleeding. Among 
the dental treatments associated with bleeding risk the following should be considered: extractions, 
placement of implants, periodontal surgery and root planing, and minor oral surgery. A risk factor in 
dental surgery is the use of local anesthetics in the sites which require surgery. 
INR values and  underlying disease 
In patients receiving anticoagulants, before proceeding we must properly assess the extent and 
effectiveness of the current therapy, that is, the INR range (clotting degree). 
Entities of therapy (INR): Before starting surgery on a patient on anticoagulant therapy it is essential to 
have a value of INR referring to the previous days because of the extreme variability of the INR. The 
dentist has the duty to evaluate on the one hand if the INR is within the therapeutic range for the 
disease from which the patient is suffering, and on the other hand if this value is compatible with the 
planned dental treatment.  
Effectiveness of therapy (underlying disease): the dentist who is going to treat a patient on 
anticoagulant therapy should be very familiar with the thromboembolic risk of the patient, that is, with 
the disease for which the therapy has been started and what INR is range required by this disease. As 
described in Figure 2, the primary goal is to keep the patient still within its therapeutic range, ie 
maintaining a INR value that exposes him/her, at the same time, to the least thrombo-embolic risk and 
to the least risk of bleeding. 
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Figure 2: Thrombotic risk and the risk of bleeding during anticoagulant therapy. 
The therapeutic range for most conditions is between 2.0 and 3.0: by increasing 
the INR there is a reduction of thrombo embolic risk (downward arrow) and an 
increase in haemorrhagic stroke (upwards arrow) and vice versa . 
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INR VALUES AND TYPE OF TREATMENT  
• INR <2.0: it is possible to perform any dental procedure, including those at high risk of 
bleeding, without modifying or suspending the anticoagulant therapy. We must assess whether 
such a low INR value corresponds to the patient's therapeutic range, otherwise his/her 
cardiologist should be contacted. 
• INR> 4.0: No dental procedure should be performed outside a hospital or specialized 
structure; for such high values of INR, a cardiologist should be contacted to alter anticoagulant 
management. Currently there are very few indications to maintain the INR> 4 and the risk of 
this value is often correlated to an incorrect control of the therapy; that is why dentists who 
experience a higher value than the patient's INR therapeutic range should immediately inform 
his/her cardiologist. 
• INR> 2.0 and <4.0: this range includes the majority of patients on anticoagulant therapy. We 
must assess the complexity of the surgery from time to time and correlate the local bleeding risk 
(type of surgery, duration, location) with the cardiologic risk (severity of heart disease), and 
with the thromboembolic event that would result from a change in the therapy. In general, in 
these cases it is indicated not to suspend the anticoagulant therapy so as to not increase the risk 
of thromboembolism but to control the bleeding through the use of tranexamic acid or other 
hemostasis adjuvants before, during and after surgery. Also, since the anticoagulant effect 
remains for several days after the discontinuation of the therapy, the practice of suspending 
anticoagulant therapy in the days preceding the intervention is not accepted today as this would 
increase the risk of thromboembolism without reducing the risk of bleeding. The change of the 
coagulation capacity is closely connected to type of treatment undergone by the patient. The 
careful examination of various types of drugs will be the subject of the next chapter. 
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4. ANTITHROMBOTIC MEDICATIONS 
4.1 ANTI-AGGREGANTS 
ASPIRIN 
Acetylsalicylic acid (ASA) is a salicylate ester of acetic acid in which the carboxyl group of salicylic 
acid is substituted in correspondence of the hydroxyl. This compound was introduced into medicine in 
1899, under the name of aspirin. It possesses a wide range of pharmacological effects which depend on 
numerous variables, including the dosage employed. In fact, while the anti-platelet effect is already 
present at reduced doses of 0.5-1 mg / kg, the analgesic and antipyretic ones require at least 5-10 mg / 
kg and the anti-inflammatory effect can only be appreciated in daily doses greater than 30 mg / kg 
(37)
. 
Aspirin induces a long-lasting functional deficiency of platelets, clinically recognizable by the 
prolongation of bleeding time. This effect seems to be almost exclusively related to the activation of a 
permanent limiting enzyme platelet metabolism of the arachidonic acid. This enzyme is known as 
prostaglandin H (PGH) synthase and is responsible for the generation of PGH2. The latter is a substrate 
for some isomerase that generate at least five different bioactive prostanoids such as thromboxane A2 
(TXA2) and prostacyclin (PGI2). Due to its activity of oxygenase (COX), the PGH synthase cycle is 
also defined and COX exists in two forms: COX-1 and COX-2. The low-dose aspirin selectively 
inhibits COX-1, while high doses of aspirin inhibit both COX-1 and COX-2. 
These differences are probably responsible, at least in part, for the necessity of using very high doses of 
aspirin to obtain the analgesic and anti-inflammatory effects, while the anti-platelet effect can be 
obtained also with the daily dosage of 30 mg 
(38)
. 
Since the inactivation of COX by aspirin is irreversible, a synthesis of the enzyme is required again to 
restore normal cell function that occurs within a few hours in the nucleated cells, but not in platelets 
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that are derived from the cytoplasmic fragmentation of megakaryocytes , so they can synthesize only 
small quantities. Therefore the duration of platelet and extra-platelet effects of a single dose of the drug 
varies greatly and is between several days and a few hours, respectively 
(39)
.
 
 
Aspirin seems to have other effects on haemostasis, beyond that produced by the inhibition of 
fibrinolysis and the suppression of coagulation 
(40)
. 
Despite the rapid clearance of aspirin, its anti-platelet effect has the duration of platelets’ life due to the 
permanent activation of COX; as a consequence, the effect of aspirin regresses only with the formation 
of new platelets. There is therefore a complete separation between the pharmacokinetic and 
pharmacodynamic effects of aspirin, which provides the possibility to administer it once a day to obtain 
the chronic anti-platelet action despite its short half-life 
(38)
. 
Randomized clinical studies indicate that low-dose aspirin may prevent arterial thrombosis both in the 
case of primary vascular events in healthy or low-risk patients (primary prevention), and in the case of 
recurrences in patients with known chronic or acute vascular occlusive disease (secondary prevention ) 
(40)
. The low-dose aspirin effects: in the newly formed human platelets  COX-1 and COX-2 are present, 
while mature platelets only express COX-1. On the other end, vascular endothelial cells express both 
COX-1 and COX-2. The TXA2, which constitutes an amplification of platelet mechanism, is 
synthesized and secreted by platelets in response to different stimuli (collagen, thrombin, adenosine 
diphosphate) and, in turn, induces irreversible platelet aggregation 
(41)
. 
On the contrary, PGI2 inhibits platelet aggregation. The reduced formation of prostanoids (TAX2, 
PGI2) in different tissues can probably explain the wide range of the pharmacological effects of aspirin, 
which constitute the basis both of its therapeutic use and of its toxicity. The TAX2 derives primarily 
from the action of COX-1 and its synthesis is therefore highly reduced by the action of aspirin, instead 
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PGI2 derives mainly from COX-2 and, consequently, its synthesis is not changed by low doses of 
aspirin 
(38)
. In conclusion, although other mechanisms have been proposed, the inhibition of platelet 
COX-1 is sufficient to explain the antithrombotic effect of aspirin at low doses. 
DIPYRIDAMOLE (PERSANTIN) 
Dipyridamole is a vasodilator which in combination with warfarin inhibits the embolization of cardiac-
valve prostheses; when used alone it has modest antithrombotic effects. 
Dipyridamole interferes with platelet function increasing the cellular concentration of cAMP. Today 
the only recommended use is in combination with warfarin for the primary post-surgery prophylaxis of 
thromboembolism in patients with prosthetic heart valves. 
TICLOPIDINE (TICLID) 
Ticlopidine belongs to the class of anti-platelet agents, and is used in all those diseases where there is a 
state of hypercoagulable blood that can lead to serious cardiovascular events (myocardial infarction, 
transient ischemia, cerebral stroke). 
Ticlopidine is a pro drug that is converted to an active thiol metabolite which binds permanently to the 
platelet receptor P2Y 
(48)
 and inhibits it preventing the aggregation of thrombocytes. It possesses, like 
aspirin, a short half-life and long duration of action: the maximum inhibition of platelet aggregation 
becomes evident only after 8-11 days of treatment. 
Before a therapeutic effect becomes evident, in fact, more days of therapy are needed and of course its 
suspension does not immediately recover the platelet function, because the recovery occurs only after a 
period of time necessary for the creation of new platelets. Among the side effects that have led to the 
dropping of the use of ticlopidine should be mentioned those of hematologic nature namely 
agranulocytosis, a serious event, or thrombotic thrombocytopenic purpura (TTP), which can occur two 
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or three weeks after therapy onset. 
CLOPIDOGREL (PLAVIX) 
It is an anti-platelet agent of the thienopyridine family. Its main use is in the treatment and secondary 
prevention of acute myocardial infarction and acute coronary syndromes. It can also be used in the 
treatment of cerebral ischemia and peripheral vascular occlusive disease.It is closely related to 
ticlopidine, but seems to have a more favorable toxicity profile with less neutropenia and leucopenia. It  
is a pro drug with slow onset of action, has a synergic effect with aspirin and the usual dose is 75 mg 
per day. 
4.2 ANTICOAGULANTS 
Anticoagulants, as their name implies, are drugs that hinder the process of blood coagulation. They can 
be divided into two groups: 
• Injectable Heparin  
• Dicumarolics, administered orally. 
HEPARIN 
Heparin is a glycosaminoglycan that is found in secretory granules of mast cells (mast cells). It is 
prepared starting from the cells of the pigs’ intestinal mucosa or from beef lung. It can be administered 
by intravenous infusion or subcutaneous injection. It is divided into high-molecular-weight heparin 
(standard) and low molecular weight (fractionated). The fractionated heparin is frequently used due to 
its easily predictable pharmaco-kinetic profile that allows to control the subcutaneous administration 
depending on the weight without laboratory monitoring. Heparin binds naturally to a blood factor, 
antithrombin III, an inhibitor enzyme that as a result of the bond with the same heparin changes 
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conformation exposing its active site. The activated AT-III in turn deactivates thrombin (factor IIa), 
factor X, and other proteases involved in blood clotting. AT-III binds specifically to a pentasaccharide 
sequence of heparin sulfate contained in the polymer sequence. GlcNAc / NS (6S) -GlcA-GlcNS (3S, 
6S) - IdoA (2S) -GlcNS (6S) 
It is the conformational change in AT-III as a result of the bond with the heparin that allows the 
deactivation of Factor Xa by antithrombin itself. This deactivation of the active X factor also requires a 
link between the heparin and pentasaccharide factor Xa itself. These interactions are possible thanks to 
the high electronegative charge density of heparin;  the formation of a ternary complex between AT-III, 
thrombin and heparin leads therefore to the deactivation of thrombin itself. The formation of the ternary 
complex thus depends on the length of the polymer heparin (at least 18 disaccharide units). The 
inactivation of factor Xa, instead, requires only the penta saccharide. 
Heparin then catalyzes the inhibition of several coagulation proteases thanks to antithrombin, a 
polypeptide synthesized by the liver which inhibits coagulation factors activated by the intrinsic and 
common pathway. 
Heparin is used as an initial treatment of venous thrombosis and pulmonary embolism, due to its fast 
action, for the initial control of patients with unstable angina or acute myocardial infarction, during and 
after coronary angioplasty or stent placement, during procedures requiring cardiopulmonary bypass and 
to prevent venous thrombo-embolism in high-risk patients after orthopedic surgery. Also it appears to 
be the drug of choice in pregnancy being unable to cross the B.E.E and not having been associated with 
birth defects. 
FRACTIONATED HEPARINS  
The new generation fractionated heparins, administered subcutaneously, are extremely easy to handle 
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drugs and their  therapeutic effect can be programmed especially for their duration, so they do not 
require to be monitored for their routine use, as for example in dialysis patients. In patients treated with 
heparin, monitoring may be required only in cases of continuous infusion; in these cases the most 
suitable laboratory test is the partial thromboplastin time (PTT). 
The question of the need to suspend the concurrent anticoagulant therapy of surgical procedures in the 
oral cavity  has been debated for many years: the protocols and standards of conduct proposed for the 
management of anticoagulation therapy in patients who are receiving dental care are numerous and 
diverse. 
WARFARIN 
It is a coumarin anticoagulant vitamin K antagonist. Various coagulation factors (prothrombin and 
factors VII, IX and X) in order to become active should undergo post translational modifications which 
consist in the carboxylation of certain glutamic acid residues, in order to generate γ-carboxyglutamic 
acid. During the reaction of carboxylation, vitamin K, which fixes and then transfers the CO2 
molecule, is converted to vitamin K epoxide which is then converted back to the previous form by 
means of a specific reductase. This enzyme is the target of the action of warfarin, which determines its 
inhibition. 
In order to make the anticoagulant effects of the drug appear, it is necessary that the pool of vitamin K 
is largely converted into epoxide. Only then, in fact, the factors of coagulation products will not be 
made active and will not be able to exert their action. In addition, some coagulation factors have a half-
life of a few days: it is necessary to wait for them to become naturally consummated or degraded to 
achieve complete pharmacological action. It is for these reasons that the effects of the drug begin to 
appear 8-12 hours after ingestion and reach maximum effect after 48-72 hours. 
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The usual dosage of warfarin in adults is 5 mg per day for 2- 4 days, followed by 2-10 mg per day as 
indicated by the values of INR. 
Latency time of oral anticoagulants 
The effects of oral anticoagulants, in contrast to those of heparin, are not immediate, but there is a 
latency time which depends on the half life of coagulation factors present in the blood and therefore 
still active (its half-life can reach up to 60 hours for some factors), as well as individual phenomena 
related to the absorption and elimination of the drug, the liver and the concomitant use of other 
substances capable of counteracting or increasing the action of these drugs. The diversity of all these 
factors makes the response to the same dose of drug extremely subjective. 
The factors with shorter half-life, such as factor VII, whose half-life is 6 hours, will disappear 
prematurely, leaving the place to inactive forms, whilst molecules such as prothrombin, factor IX and 
factor X which have half-lives of 60 , 24 and 40 hours, respectively, will require longer times. 
Since the beginning of anticoagulation, therefore, it takes several days before getting a full 
anticoagulant effect; Similarly, after stopping the drug, it takes as many days  to return to normal 
clotting. 
The question of the need to suspend the concurrent anticoagulant therapy of surgical procedures in the 
oral cavity has been the subject of debate for many years: the protocols and standards of conduct 
proposed for the management of anticoagulation therapy in patients who are receiving dental care are 
numerous and mutually different. 
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4.3 NEW GENERATION ORAL ANTICOAGULANTS 
DABIGATRAN 
The direct thrombin inhibitors act by modulating the transformation of fibrinogen into fibrin and inhibit 
the thrombin-mediated activation of factors V, VII, XI, XII with anticoagulant effect; the block of 
thrombin determines also an inhibition of its receptor-mediated effects or platelet aggregation. 
Dabigatran
(60,63)
, a potent reversible direct thrombin inhibitor, both in its free form and when bound to 
fibrin, inhibits the activity of thrombin but also its generation. Dabigatran produces predictable and 
consistent pharmacodynamic effects, therefore it does not require regular coagulation monitoring or 
dose adjustment. In the course of the treatment the level of anticoagulation can be evaluated by 
measuring the "thrombin clotting time" although it is not yet a standardized test, or  the '' ecarin clotting 
time " a test, however not easily available on a large scale; these assays may be useful in case of 
bleeding and in case of suspected overdose, conditions in which even the aPTT may be lengthened. 
Alongside the efficacy results and safety of the therapy with dabigatran further advantages are 
represented by the lower inter-individual variability of response, by the lower profile of drug 
interactions and by the fact that the routine monitoring of coagulation is not needed; disadvantages 
linked to the new therapy are traced to the lack of availability of a specific antidote of dabigatran, 
therefore in case of severe bleeding supportive therapy with blood transfusions and plasma transfusions 
are required; to the twice-daily dosing that may reduce the therapeutic compliance and the high cost. 
As pointed out in the update of the American guidelines because of the twice-daily dosing and the 
highest risk of non-bleeding side effects associated with the inhibitor of thrombin, patients taking 
warfarin with excellent INR control would not derive many benefits from the therapeutic switch; as 
opposed to those with poorly controlled INR, requiring frequent dose adjustments or frequent 
monitoring of coagulation, and with high probability of drug interaction. 
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RIVAROXABAN-APIXABAN 
Factor Xa is a tempting target for the design of new anticoagulant molecules;  positioned at the 
beginning of the common pathway of the coagulation cascade its inhibition increasingly reduces the 
formation of thrombin upstream, but does not block the circulating thrombin whose traces can 
intervene in hemostasis giving this therapeutic strategy a greater safety profile regarding the risk of 
bleeding. Rivaroxaban has been approved for the prevention of venous thromboembolism in patients 
undergoing hip and knee replacement surgeries and its efficacy in atrial fibrillation has also been 
assessed. FDA regulations regarding the use of this molecule are awaited;  currently the use of 
rivaroxaban has been suggested in patients with inadequate response or who cannot take warfarin or 
dabigatran. 
4.4 LOCAL HEMOSTATICS 
To control bleeding the dentist has numerous both systemic and topical pharmacological aids; the latter 
include: 
 Oxidized regenerated cellulose: fibrous, fibril-structured, sterile, absorbable haemostatic plug 
achieved through the controlled oxidation of regenerated cellulose. Once saturated with blood, it swells 
and becomes a gelatinous mass that contributes to the formation of the clot. It is also a bactericidal 
agent against several strains; therefore, it does not increase the risk of infection 
(18,23)
. 
 Absorbable gelatin: consists of a sponge of haemostatic absorbable gelatin, insoluble in water, at a 
constant porosity, digested in pepsin and sterile; It is an implantable hemostat and like all haemostatic 
gelatin sponges is intended to facilitate the arrest of bleeding, not to be used on infected wounds; it may 
or may not be associated with tranexamic acid 
(20)
. 
 Collagen: invasive device intended for short-term use, it is manufactured utilizing animal tissue 
(9,30)
. 
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 Fibrin based glues: They contain thrombin, pro-accelerin, calcium, factor XIII and antifibrinolytic 
substances that lead to the formation of fibrin locally and reduce fibrinolysis 
(15,18,19,20,21,22,23)
. 
 Glues based on cyanoacrylates: They consist of a synthetic surgical glue based on cyanoacrylate, 
when they come into contact with the wound, they polymerize rapidly creating an elastic film; they 
have an adhesion and haemostatic action 
 PRP (Platelet-Rich Plasma) is a derivative plasmatic autologous, obtained after 2 centrifugations 
from the patient's blood, obtained with the addition of calcium and bovine thrombin that activate the 
coagulation cascade; its preservation is possible for a few days at a -19 ° C temperature. Scientific 
studies (Galindo-Moreno et al. 2005) have confirmed and highlighted the presence of fibrillar and 
cellular components SEM and TEM (mainly platelets). This structure would be capable of being a 
vehicle for cells and growth factors (PDGF, TGF-BETA, IGF) indispensable for the regeneration of 
soft and hard tissues (Marx et al. 1998; Anitua et al. 1999). The disadvantage of the PRP is the modest 
risk of anti-thrombin antibody formation for the activation of PRP with heterologous thrombin and 
high amount of blood to be taken; there are also legal medical problems regarding the handling of 
biological material that cannot be performed by the dentist. 
Among the haemostatic agents used systemically there are: 
• Synthetic antifibrinolytic Amino acids: two synthetic amino acid lysine derivatives, epsilon-
aminocaproic acid (EACA) and tranexamic acid, have high anti-fibrinolytic activity in humans 
(24,26,32)
. 
Both drugs bind reversibly to plasminogen and thus block the binding of plasminogen to fibrin itself 
and its activation to plasmin. Their distribution in the extravascular space and their accumulation in 
tissues is at the basis of efficacy in hemorrhagic conditions caused by local hyper-fibrinolysis. The 
aminocaproic acid and tranexamic acid (which is about 10 times more potent and has a longer half-life) 
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are effective even when the bleeding is not associated with signs of hyperfibrinolysis laboratory. They 
can be administered both orally and intravenously; they are eliminated in active form in the kidney, 
they are concentrated in the urine (up to 100 times) and pass in other body fluids (CSF, synovial fluid 
and sperm). 
• Aprotinin is a polypeptide with a molecular weight of 6512, extracted from bovine lung. It inhibits 
several serine proteases such as trypsin, the chemotripsin, plasmin and kallikrein, through the formation 
of a reversible enzyme-inhibitor complex. By inhibiting kallikrein, aprotinin indirectly inhibits the 
activation of factor XII, and then the start of coagulation and fibrinolysis induced by blood contact with 
‘foreign’ surfaces. Through inhibition of kallikrein, aprotinin also reduces complement activation and 
renin-angiotensin system and the inflammatory response triggered by kallikrein. Aprotinin does not 
interfere with platelet function. It is inactive orally and is administered with an initial loading dose 
followed by continuous intravenous infusion. The enzymatic activity is expressed in units inactivating 
kallikrein (KIU), 1 mg of aprotinin being equivalent to 7,143 KIU. Concentrations of 125 KIU / mL are 
necessary to inhibit plasmin and concentrations from 300 to 500 KIU / ml are needed to inhibit 
kallikrein. 
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5. EXPERIMENTAL AND CLINICAL STUDY 
5.1 MATERIALS AND METHODS 
 
Materials 
Tranexamic acid, magnesium stearate, sodium chloride, disodium hydrogen phosphate, and potassium 
dihydrogen phosphate, sodium carboxymethylcellulose (CMC; 700kDa) were purchased from Sigma-
Aldrich (Milan, Italy). Spray-dried lactose was obtained from Polichimica s.r.l (Bologna, Italy). 
Alginate sodium salt (ALG; low viscosity, 250 centipoise for a 2% dispersion) was purchased from 
Farmalabor (Canosa di Puglia, BT, Italy). Polyethyleneoxide NF grade (PEO; Polyox WSR-301; 4000 
kDa) was purchased from Colorcon (Dartford Kent, UK). 
TrA Quantitative Analysis 
Tranexamic acid was quantified after derivatization with fluorescamine by UV spectrophotometry.
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Briefly, a fluorescamine solution in ethanol (0.5 mg/mL) was added to a TrA solution in phosphate-
buffered saline (PBS) (2.38 g Na2HPO4) × 12 H2O; 0.19 g KH2PO4; 8 g NaCl in 1 L water adjusted at 
pH 7.4) at a 1:1 vol/vol ratio. After 1-hour incubation in the dark, the sample was analyzed by UV at 
392 nm on Shimadzu UV-1204 apparatus (Shimadzu, Milan, Italy) fitted out with a 0.1-cm quartz cell 
(Hellma Italia, Milan, Italy). Linearity of response was verified in the 5- to 100-µg/mL concentration 
range (R
2
=0.999). 
Matrix Preparation 
Matrices were prepared by direct compression of TrA (50 mg), bioadhesive polymer (ie, CMC, ALG, 
or PEO) (48 mg), lactose (379.6 mg), and magnesium stearate (2.4 mg) by a manual hydraulic press 
(Specac Ltd, Slough, UK). All the components were preliminarily milled, sieved through a 90-µm 
sieve, and mixed in a Turbula apparatus (Willy A. Bachofen AG, Muttenz, Switzerland). Matrices were 
prepared with a diameter of 1.3 cm (Fig. 2). Their hardness was checked using a handheld tablet 
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hardness tester Monsanto type. The instrument measures the force required to break the matrix when 
the force generated by a coil spring is applied diametrically to the tablet. 
 
Release Kinetics of TrA 
Release kinetics of TrA from matrices were evaluated according to the dissolution test method, 
apparatus 1 reported in the European Pharmacopoeia (Ph. Eur), 7th edition. Release was performed in 
500 mL PBS at 37°C and 30 revolutions/min. At predetermined intervals, 2 mL was withdrawn and 
assessed for TrA content as reported above. Results were compared with dissolution profile of TrA 
powder according to dissolution test method, apparatus 2. The concentration of TrA in the surrounding 
medium was always below maximum solubility. Results are reported as percentage of TrA released ± 
SD of 4 replicates. 
 
Swelling/Erosion Kinetics of Tablets 
Matrix swelling was evaluated in PBS by measuring weight over time. Matrix was secured in a basket 
made of aluminum net and placed in 10 mL of medium at 37°C. At predetermined intervals, matrices 
were withdrawn, gently blotted with filter paper, and weighted. Results are expressed as the ratio 
between matrix weight at time t (Wt) and initial matrix weight (W0) ± SD on 4 samples.  
Matrix erosion was evaluated under the same conditions as those described above for swelling. A 
sample was prepared for each testing time. At predetermined intervals, the medium was withdrawn; the 
matrix was dried up to constant weight at 40°C in a vacuum. The fractional weight loss (WL) of the 
matrix was calculated using the following equation: 
i
ti
W
)WW(
WL


  
where W0 is the initial weight of the matrix, and Wt is the weight of the matrix at time t. The results are 
expressed as mean ± SD of 4 replicates. 
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Subjects and Methods 
From September 2008 to April 2011, 84 patients undergoing single or dual anticoagulation therapy (48 
women and 36 men) from the Department of Neurosciences and Reproductive and Odontostomatologic 
Science of the University of Naples “Federico II” were selected for the study. The study was a 
Randomized Clinical Trial. 
Patient ages ranged from 39 to 74 years (mean age was 56.5 years). Thirty-four patients (40.4%) had a 
history of hypertension, 21 patients (25.0%) of ischemic heart disease, and 11 (13.0%) of 
cerebrovascular disease. In addition, 9 (10.8%) had coronary artery stents, and 9 had (10.8%) cardiac 
dysrhythmias. Fifty-one patients (60.8%) were receiving single antiplatelet therapy with clopidogrel or 
ticlopidine. The remaining 33 patients (39.2%) were undergoing dual antiplatelet therapy with aspirin 
and clopidogrel or ticlopidine. 
At the moment of the study, they needed at least 2 dental extractions; they were on oral anticoagulant 
therapy, and their INR range was from 2 to 4. 
The patients were randomized by the flip of a coin into 2 different therapeutic approaches: 
  control group (31 patients), where the extractions (157 in total) were performed after 
suspending the oral anticoagulant therapy a few days before the operation, reaching a 
patient’s INR less than 2 
 study group (53 patients), where the extractions (173 in total) were performed maintaining 
the patient’s dose regimen of anticoagulant therapy unchanged; the control of hemostasis in 
the residual socked was carried out by refilling it with a new absorbable swelling sponge 
loaded with TrA (Figs. 3,4,5,6,7). 
The patients’ INR was assessed in the 24 hours preceding oral treatment. In both groups, the 
extractions were performed with minimal bone trauma and followed by an instrumental screening of 
the residual bone and a resorbable ‘mattress’ suture. 
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The postoperative protocol did not include the use of cephalosporins , macrolides, quinolones, which 
have been shown to have a potential in interfering with the coagulation cascade.
31
 To prevent 
infections, the patients were treated with intramuscular teicoplanin 200 mg once a day and 
intramuscular Nebcin (tobramycin for injection) 5 mg/kg twice a day at 2 days before and 4 days after 
surgical procedures. Diclofenac was used as an analgesic for its limited effects on blood coagulation. 
We excluded patients having systemic bleeding disorders (von Willebrand disease, hemophilia) or 
systemic conditions that caused coagulopathies (liver disease). All patients signed an informed consent 
before participating in the study, which was reviewed and approved by the University institutional 
review board.  
The differences in postoperative bleeding ( immediate and delayed) and the need of its treatment at the 
hospital among the 2 groups were evaluated. χ2 Test was used to test differences in the prevalence of 
postoperative bleeding between groups. 
 
5.2 RESULTS 
Matrix Loaded With TrA 
Three different types of matrices based on spray-dried lactose/mucoadhesive mixtures were prepared 
by direct compression. CMC, PEO, or ALG were selected as mucoadhesive component. Tranexamic 
acid-containing matrices displayed a crushing strength around 4 kg, which is a typical value for softer 
sublingual and chewable tablets.  
Matrix swelled without disintegrating up to 60 minutes, thus suggesting that a 10% of the weight of 
mucoadhesive polymer was suitable to avoid fast matrix disintegration once in contact with an aqueous 
medium. Furthermore, swelling/erosion profiles highlighted that matrices made of ALG and CMC 
absorbed a high amount of water in the early hydration stage and increased their weight around 1.5 and 
2.5 folds, respectively. 
 36 
Swelling of PEO was slower and reached its maximum in around 2 hours. After initial water uptake, 
matrices started eroding because of progressive polymer and TrA dissolution in the aqueous medium. 
Tranexamic acid is a very hydrophilic drug, and its dissolution is practically instantaneous. On the 
other hand, the incorporation of TrA in the matrices allowed its slow and sustained release at a rate 
depending on the type of bioadhesive polymer added. Because of fast swelling and TrA release rate, 
ALG matrices were considered the most appropriate candidate to test in vivo performance. 
Clinical Study 
All the individuals completed the study, and the protocol achieved good results. There were no 
significant differences between the groups in the mean age, proportions of men/women, and number of 
teeth extracted. 
Naturally, the mean INR for the anticoagulant group was significantly higher at 2 than that for the 
control group at 1.6 (P≤ 0.001). 
No differences in the prevalence of postoperative bleeding were found (P=0.136). 
There were only 6 hemorrhagic complications (7.2%). Four patients of the control group presented a 
late postoperative hemorrhage between 2 and 4 days after extraction period-related to the formation of 
a very large coagulum. The first of these four patients was a 63-year-old woman receiving a dual 
anticoagulation therapy for a coronary artery stent (INR= 2.8); her hemorrhage was stopped, by  
making a careful and meticulous curettage of the alveolus, re-suturing under local anesthesia, and 
applying pressure with gauze moistened with TrA. The same technique was used to control the 
bleeding of the other 3 patients of the control group who had a history of hypertension. 
 Two patients of the study group showed an immediate postoperative hemorrhage even after the 
placement of the matrix that swelled and was retained inside the wound with the suture. A second 
subsequent correct placement of the new matrix was sufficient to control the bleeding and ensure an 
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adequate clot formation. In all cases, the study group did not require further hospitalization or systemic 
therapy. 
 
5.3 DISCUSSION 
Recently, several authors suggested that levels of anticoagulation can be maintained and any sub-
sequent post-extraction hemorrhage be treated with local treatments such as suturing and/or in situ 
application of hemostatic agents. The aim of this strategy is to minimize the risk of adverse 
thromboembolic events including embolic stroke, myocardial ischemia, or even death.
6
 The incidence 
of thromboembolism due to a short-term interruption of anticoagulation therapy within the 30-day 
follow-up period was identified as ranging from 0.5% to 1%.
33, 34
 To avoid interruption or a reduction 
of the anticoagulation therapy, thus diminishing the intra-intervention and post-intervention bleeding 
risk, the same authors demonstrated the clinical advantage of the anti-fibrinolytic effect of TrA 
solutions.
19 
The solution was used as a mouthwash or to soak microfibrillar oxidized regenerated 
cellulose, where it has proved particularly effective in preventing postoperative bleeding.
26 
However, 
many authors reported how early bone healing after the placement of oxidized cellulose appeared to be 
impeded.
27-30
 In our research, TrA was integrated in a cellulose swelling matrix able to conform to the 
tridimensional post-extractive alveolar cavity, ensuring also a mechanical contribution to  homeostasis. 
The design of the hemostatic matrix was carried out taking into account that the matrix should (i) 
provide intermediate mechanical properties suitable to confer  appropriate resistance to the matrix as 
well as the possibility of cutting it at a size suitable for insertion inside the alveolar cavity, (ii) rapidly 
swell once in contact with blood forming a muco adhesive plug, and (iii) disintegrate rapidly after TrA 
delivery. To this purpose, we selected 3 well-known mucoadhesive polymers safely used in 
pharmaceutical dosage forms. The amount of mucoadhesive polymer was maintained as low as 
possible to avoid the formation of a slowly swellable glassy hydrophilic matrix releasing the drug at too 
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slow a rate. On the other hand, the amount of lactose used was maintained high to promote the fast 
hydration and erosion of the matrix while guaranteeing mucoadhesion and avoiding disintegration. 
The crushing strength, which is an indicator of the strength required to break a matrix in the diametric 
compression test, had to be high enough to withstand mechanical stress during packaging, shipment, 
and handling by the consumer.
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 Values obtained can be considered suitable to attain resistance of the 
mucoadhesive matrices to abrasion or breakage under conditions of storage, transportation, and 
handling before usage. Swelling/erosion of the matrices occurred because of matrix hydration, 
solubilisation of mucoadhesive component, lactose, and drug. Thus, initial water uptake was 
accompanied by a weight increase and followed by a progressive weight loss of the matrix. Upon 
hydration, the disentanglement of polymer chains starts to occur as a function of polymer 
hydrophilicity, with the PEO matrix being the slowest to reach maximum water uptake and erode 
completely. Furthermore, the addition of a very limited amount of a hydrophilic polymer in the matrix 
was sufficient to keep it intact over time, for it to absorb a  good amount of blood  and erode itself by 
releasing  a suitable amount of TrA.  The swelling/erosion profiles were directly related to TrA release 
rate: the faster the erosion of the matrix, that is ALG, the faster the release rate. 
Taken together, these results highlight how the compositions proposed, especially TrA-ALG matrix, 
can perfectly fit an application in the alveolar cavity, where the system should work as a physical plug 
able to absorb blood, release TrA, and erode very rapidly. 
The clinical outcome of the system was very satisfactory, highlighting several advantages of this new 
delivery system for TrA after extraction in patients receiving anticoagulant therapy. In terms of 
activity, the TrA-loaded system was able to promote an adequate homeostasis without the suspension 
or reduction of anticoagulant therapy and, as a consequence, no additional thromboembolic risk.  
As a consequence, hospitalization can be reduced with a net benefit in socioeconomic terms. 
Furthermore, the developed matrices have peculiar swelling (Figs. 8A, B) and mucoadhesive 
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properties, a reasonable cost and reduced expenses, including hospitalization. Patients had no infectious 
risk (high compatibility), and owing to its synthetic nature, there is no risk of transmissible disease 
related to the use of the cellulose sponge as compared with the fibrin adhesive, which derives from a 
pool of patients.
36
 
The limitations of the present study include the small sample size (n= 84); a larger experimental 
population may be needed to elucidate the safety of this approach. However, it is clear that the use of 
an advanced delivery system for TrA with the discontinuation of  warfarin therapy and  INR in 
therapeutic range, is safe and effective. 
 
5.4 CONCLUSIONS 
Bioadhesive swelling systems loaded with TrA and especially those prepared with ALG due to their 
peculiar composition, show fast swelling, drug release and erosion, so they are particularly fit for an 
application as an intra-alveolar medicated plug. Clinical studies demonstrate that the system is 
therapeutically relevant in patients at risk undergoing systemic anticoagulant therapy. 
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Fig. 3: Shape and size of the matrix used in the clinical trial   
 
Fig. 4: Extraction with minor bone trauma 
 
 
 
 
Fig. 5: Placing of the loaded matrix in the newly formed oral cavity 
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Fig. 6: Suturing of the absorbable stitches with the ‘mattress’ technique  
 
 
 
 
 
Fig. 7: Hemostasis obtained after the operation in the sites under observation 
 
 
 
 
 
 A                   B    
 
Fig 8A and B: Swelling matrix apply pressure inside alveolar cavity, ensuring an 
adequate clot formation 
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